TickerFacts.

Alumis Inc. (ALMS): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$3.50M
Year ended 2025-12-31
$3.53M
Trailing 12 months to 2026-06-30
2023-12-31: $1.28M2024-12-31: $3.15M2025-12-31: $3.50M$3.50M
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$3.50M+10.9%2026-03-19, From 2025-01-01
2024-12-31$3.15M+145.5%2026-03-19, From 2024-01-01
2023-12-31$1.28Mn/a2025-03-19, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Alumis Inc. (ALMS)2025-12-31$3.50M+10.9%
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$220.0K+94.7%
Celularity Inc (CELU)2025-12-31$7.29M-7.9%
Cue Biopharma, Inc. (CUE)2025-12-31$958.0K+141.3%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$1.20M-7.7%
Scynexis Inc (SCYX)2024-12-31$0-100.0%
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$109.0K-53.2%
Foghorn Therapeutics Inc. (FHTX)2025-12-31$3.33M+6.8%
Bioharvest Sciences Inc. (BHST)2025-12-31$1.62M+29.8%

Compare ALMS, NAMS, CELU, CUE side by side · Screen every company in Pharmaceutical Preparations ↗